Amneal Pharmaceuticals (AMRX) Aktienübersicht
Amneal Pharmaceuticals, Inc. ist ein globales biopharmazeutisches Unternehmen, das Generika, injizierbare Arzneimittel, Biosimilars und spezielle pharmazeutische Markenprodukte in den Vereinigten Staaten, Indien, Irland und international entwickelt, herstellt, vermarktet und vertreibt. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 2/6 |
| Künftiges Wachstum | 4/6 |
| Vergangene Leistung | 2/6 |
| Finanzielle Gesundheit | 1/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
AMRX Community Fair Values
Create NarrativeSee what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Amneal Pharmaceuticals, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$16.92 |
| 52-Wochen-Hoch | US$17.86 |
| 52-Wochen-Tief | US$7.67 |
| Beta | 1.26 |
| 1 Monat Veränderung | 23.05% |
| 3 Monate Veränderung | 37.34% |
| 1 Jahr Veränderung | 101.19% |
| 3 Jahre Veränderung | 462.13% |
| 5 Jahre Veränderung | 251.77% |
| Veränderung seit IPO | 12.72% |
Aktuelle Nachrichten und Updates
Analyseartikel • Jun 21
Amneal Pharmaceuticals (AMRX) Stock Could Be 6% Below Fair Value After Its Sharp Rally
Why Amneal Pharmaceuticals Stock Is On Investors’ Radar Amneal Pharmaceuticals (AMRX) has been drawing attention after a strong share price move over the past month and past 3 months, prompting investors to reassess what the current valuation implies. The stock recently closed at US$16.21, and available data shows it trades at a discount to one independent intrinsic value estimate. This may interest readers comparing Amneal to other US biopharmaceutical companies. See our latest analysis for...
Narrativ-Update • Jun 19
AMRX: Biosimilar Buildout And 2026 Execution Will Shape Fairly Valued Stock
Analysts have nudged their fair value estimate for Amneal Pharmaceuticals up to $17.25 from $17.20, citing higher projected profit margins and renewed confidence in the 2026 outlook as the company works to narrow its valuation gap with peers and advance its biosimilar efforts. Analyst Commentary Recent research on Amneal Pharmaceuticals highlights a mix of optimism on the 2026 setup and some areas where investors may want to stay disciplined on execution and valuation.Recent updates
Analyseartikel • Jun 21
Amneal Pharmaceuticals (AMRX) Stock Could Be 6% Below Fair Value After Its Sharp Rally
Why Amneal Pharmaceuticals Stock Is On Investors’ Radar Amneal Pharmaceuticals (AMRX) has been drawing attention after a strong share price move over the past month and past 3 months, prompting investors to reassess what the current valuation implies. The stock recently closed at US$16.21, and available data shows it trades at a discount to one independent intrinsic value estimate. This may interest readers comparing Amneal to other US biopharmaceutical companies. See our latest analysis for...Narrativ-Update • Jun 19
AMRX: Biosimilar Buildout And 2026 Execution Will Shape Fairly Valued Stock
Analysts have nudged their fair value estimate for Amneal Pharmaceuticals up to $17.25 from $17.20, citing higher projected profit margins and renewed confidence in the 2026 outlook as the company works to narrow its valuation gap with peers and advance its biosimilar efforts. Analyst Commentary Recent research on Amneal Pharmaceuticals highlights a mix of optimism on the 2026 setup and some areas where investors may want to stay disciplined on execution and valuation.Narrativ-Update • Jun 04
AMRX: Biosimilar Execution And 2026 Outlook Will Support Share Rebound
Analysts have inched their fair value estimate for Amneal Pharmaceuticals up from $17.00 to $17.20 and raised the price target to $16.00, citing stronger confidence in the fiscal 2026 outlook, a solid Q1 update, and an increasing focus on biosimilar opportunities compared with peers. Analyst Commentary Bullish Takeaways Bullish analysts point to the recent Q1 report as a key support for their higher fair value estimates, viewing the current execution as consistent with their fiscal 2026 expectations.Narrativ-Update • May 04
AMRX: 2026 EBITDA Outlook Will Support Rebound After GRx Driven Pullback
Amneal Pharmaceuticals' consensus analyst price target has shifted to $17.00, with analysts citing solid Q4 results, strengthened FY26 EBITDA guidance and a reset future P/E assumption as support for this updated view. Analyst Commentary Recent research has focused on how Amneal Pharmaceuticals' updated FY26 guidance and Q4 performance feed into valuation, growth expectations and execution risk around that new US$17.00 price target.Seeking Alpha • Apr 21
Amneal: A Robust Drug Portfolio Worth Watching, Driving Further Upside Potential
Summary Amneal Pharmaceuticals, Inc. remains a Buy, driven by robust top-line growth, a diversified drug pipeline, and macro demand in key clinical areas. AMRX's FY2025 revenue grew 8% to $3.02B, with positive FY26 guidance and outperformance of Crexont and Brekiya drugs supporting the growth thesis. Despite negative equity and below-investment grade credit, AMRX's 15.2% operating cash flow growth and undervaluation versus peers helps support a bullish outlook. Key risks include drug trial failures, regulatory setbacks, and litigation, but AMRX's pipeline diversification and macro tailwinds across clinical areas bolster its medium-to-long-term potential. Read the full article on Seeking AlphaNarrativ-Update • Apr 19
AMRX: 2026 EBITDA Plan And Inhalation Entry Will Drive Bullish Setup
Amneal Pharmaceuticals' analyst price target has shifted from $16.80 to about $17.17, with analysts pointing to recent target increases to $17 following solid Q4 results, 2026 EBITDA guidance strength, and a still intact long term growth thesis as key support for the updated view. Analyst Commentary Recent Street research around Amneal Pharmaceuticals has been concentrated on Q4 results, the new 2026 outlook, and how these feed into revised targets near $17.Narrativ-Update • Apr 02
AMRX: 2026 EBITDA Plan And Affordable Medicines Theme Will Drive Bullish Setup
Analysts have raised their price targets on Amneal Pharmaceuticals from $15 to $17, citing solid Q4 results, 2026 guidance that highlights stronger EBITDA expectations, and continued interest in the affordable medicines theme as key supports for the updated view. Analyst Commentary Analysts raising targets to $17 are largely focused on how Amneal executes against its 2026 plan and how that ties into the affordable medicines theme and EBITDA outlook.Narrativ-Update • Mar 18
AMRX: 2026 EBITDA Guidance Will Shape Bullish Setup Despite Recent Pullback
Narrative Update on Amneal Pharmaceuticals The analyst price target for Amneal Pharmaceuticals has been revised higher from $16.40 to $16.80. Analysts point to stronger FY26 EBITDA guidance and recent target increases to $17 at multiple firms as support for the updated view.Narrativ-Update • Mar 04
AMRX: 2026 EBITDA Outlook And Index Adds Will Shape Bullish Setup
Analysts have lifted their price target on Amneal Pharmaceuticals from $15.20 to $16.40, citing recent target hikes to $17 following solid Q4 results and 2026 guidance. The guidance highlights stronger EBITDA expectations despite more tempered revenue and margin assumptions, along with a higher future P/E of about 50x.Narrativ-Update • Feb 17
AMRX: Affordable Medicines Theme And Index Adds Will Shape Measured 2026 Setup
Analysts have nudged their price targets on Amneal Pharmaceuticals higher, with the updated fair value estimate moving from $14.40 to $15.20. This change is supported by recent Street research highlighting continued interest in affordable medicines and the company's role in that theme.Narrativ-Update • Feb 03
AMRX: Affordable Medicines Theme And Index Adds Will Shape Balanced 2026 Outlook
Analysts recently lifted their price target on Amneal Pharmaceuticals to $15 from $14, citing the company’s exposure to the affordable medicines theme as a key factor supporting their updated view. Analyst Commentary Recent commentary around Amneal Pharmaceuticals centers on its role in the affordable medicines theme and how that ties into expectations for execution and valuation heading into 2026.Narrativ-Update • Jan 19
AMRX: Affordable Medicines Theme And Q3 Execution Will Guide Fairly Balanced Outlook
Narrative Update Analysts have lifted their implied price target on Amneal Pharmaceuticals to about $14.40 from $14, reflecting higher Street targets of up to $15 and supportive views on both the affordable medicines theme and the company’s recent Q3 results versus expectations. Analyst Commentary Recent research updates focus on Amneal Pharmaceuticals' role in affordable medicines and the implications of its latest quarterly results for valuation and execution.Narrativ-Update • Jan 05
AMRX: Complex Generics Pipeline And Recent EPS Beat Will Shape Outlook
Analysts have nudged their fair value estimate for Amneal Pharmaceuticals higher to US$14.00 from US$13.80, reflecting updated price targets and recent quarterly results that came in ahead of prior Street EPS and revenue estimates. Analyst Commentary Bullish Takeaways Bullish analysts highlight that Q3 adjusted diluted EPS of US$0.17 came in ahead of prior Street expectations of US$0.14, which they see as a sign of solid execution against current earnings targets.Narrativ-Update • Dec 13
AMRX: Complex Generics Approvals Will Support Future Earnings Upside
Analysts have modestly raised their price target on Amneal Pharmaceuticals to approximately $13.80 from about $13.50, reflecting better than expected earnings and revenue performance in the latest quarter. Analyst Commentary Bullish Takeaways Bullish analysts highlight the earnings beat, with adjusted diluted EPS exceeding Street expectations, as evidence that management is executing effectively on cost control and product mix.Analyseartikel • Nov 30
Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Despite an already strong run, Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) shares have been powering on, with a gain...Narrativ-Update • Nov 29
AMRX: Continued Execution and Pipeline Milestones Will Support Balanced Outlook
Analysts have raised their price target for Amneal Pharmaceuticals from $11 to $13, citing the company's stronger than expected third-quarter results and improved earnings outlook. Analyst Commentary Following the recent quarterly results, analysts have weighed in on Amneal Pharmaceuticals with a focus on both the company's strengths and areas for caution as they consider the revised price target.Narrativ-Update • Nov 15
AMRX: Sustained Outperformance Will Drive Future Earnings Confidence
Analysts have increased their price target for Amneal Pharmaceuticals from $11 to $13. They cite the company’s better-than-expected third-quarter earnings and revenue performance as the reason for this adjustment.Analyseartikel • Nov 14
Amneal Pharmaceuticals' (NASDAQ:AMRX) Earnings May Just Be The Starting Point
Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) recently posted some strong earnings, and the market responded positively...Narrativ-Update • Nov 01
AMRX: Recent FDA Approvals And Pipeline Launches Will Drive Upside Momentum
Amneal Pharmaceuticals’ analyst price target has risen from $12.67 to $13.50, as analysts cite stronger revenue growth and an improved earnings outlook following the company’s recent results. Analyst Commentary Recent analyst updates indicate a mix of optimism and caution following Amneal Pharmaceuticals’ latest quarterly performance and forward guidance.Narrativ-Update • Sep 17
Global Health Trends And Pipeline Launches Will Fuel Future Potential
Amneal Pharmaceuticals' consensus price target has been raised as analysts now assign a higher future P/E multiple, increasing their fair value estimate from $12.00 to $12.67. What's in the News Amneal received FDA approval for its sodium oxybate oral solution 500 mg/mL (generic for Xyrem) for narcolepsy, expanding beyond prior limited authorized generic distribution.Analyseartikel • Aug 08
Results: Amneal Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
It's been a good week for Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) shareholders, because the company has just...Analyseartikel • Jul 24
Why Investors Shouldn't Be Surprised By Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Low P/S
With a price-to-sales (or "P/S") ratio of 0.9x Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) may be sending very bullish...
Neues Narrativ • Mar 22
CREXONT And Metsera Partnerships Will Capitalize On Growing GLP-1 Market
The strategic collaboration in GLP-1 therapies and biosimilars expands market reach, poised to drive significant future revenue growth.Seeking Alpha • Mar 19
Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued
Summary Amneal Pharmaceuticals, Inc. seems fundamentally undervalued, with a market cap significantly lower than peers despite similar revenue levels, suggesting potential for substantial stock price appreciation. The company reported strong 2024 financials, with revenues up 17% year-on-year, and forecasts continued growth in 2025, driven by diverse product segments. Amneal is reducing debt effectively, targeting a net debt to EBITDA ratio of 3.6-3.7 in 2025, enhancing financial stability and investor confidence. Key growth areas include biosimilars, specialty drugs like CREXONT, and the high-growth GLP-1 weight loss market, positioning AMRX stock for long-term success. Read the full article on Seeking AlphaAktionärsrenditen
| AMRX | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | -2.1% | 1.4% | 1.6% |
| 1Y | 101.2% | 48.6% | 18.6% |
Rendite im Vergleich zur Industrie: AMRX übertraf die Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 48.6 erzielte.
Rendite vs. Markt: AMRX übertraf den Markt US, der im vergangenen Jahr eine Rendite von 18.6 erzielte.
Preisvolatilität
| AMRX volatility | |
|---|---|
| AMRX Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: AMRX hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: AMRXDie wöchentliche Volatilität (5%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2002 | 8,700 | Chirag Patel | www.amneal.com |
Amneal Pharmaceuticals, Inc. ist ein globales biopharmazeutisches Unternehmen, das Generika, injizierbare Arzneimittel, Biosimilars und spezielle pharmazeutische Markenprodukte in den Vereinigten Staaten, Indien, Irland und international entwickelt, herstellt, vermarktet und vertreibt. Das Unternehmen ist in drei Segmenten tätig: Erschwingliche Arzneimittel, Spezialitäten und AvKARE. Das Segment Erschwingliche Arzneimittel bietet Darreichungsformen und Verabreichungssysteme an, darunter Feststoffe mit sofortiger und verlängerter Wirkstofffreisetzung, Pulver, Flüssigkeiten, sterile Injektionspräparate, Nasensprays, Inhalations- und Atemwegsprodukte, Biosimilar-Produkte, Augenheilmittel, Filme, transdermale Pflaster und topische Produkte.
Amneal Pharmaceuticals, Inc.'s Grundlagenzusammenfassung
| AMRX grundlegende Statistiken | |
|---|---|
| Marktanteil | US$5.47b |
| Gewinn(TTM) | US$122.12m |
| Umsatz(TTM) | US$3.05b |
44.2x
Kurs-Gewinn-Verhältnis 1.8x
Kurs-Umsatz-VerhältnisIst AMRX zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| AMRX Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$3.05b |
| Kosten der Einnahmen | US$1.85b |
| Bruttogewinn | US$1.19b |
| Sonstige Ausgaben | US$1.07b |
| Gewinn | US$122.12m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 0.38 |
| Bruttomarge | 39.16% |
| Nettogewinnspanne | 4.01% |
| Schulden/Eigenkapital-Verhältnis | 6,438.6% |
Wie hat sich AMRX auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/06 23:49 |
| Aktienkurs zum Tagesende | 2026/07/06 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Amneal Pharmaceuticals, Inc. wird von 20 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Glen Santangelo | Barclays |
| Gary Nachman | BMO Capital Markets Equity Research |
| David Buck | B. Riley Securities, Inc. |